Jia Su
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jia Su has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Qinglin Yu
Department of Traditional Chinese Internal Medicine, The First Affiliated Hospital of Ningbo University
12 shared publications- Xiaomin Chen
Department of Cardiology, The First Affiliated Hospital of Ningbo University
12 shared publications Jin Yang
10 shared publicationsJiyi Li
Department of Cardiology, Yuyao People's Hospital of Zhejiang Province, Yuyao, Zhejiang, China
7 shared publicationsJiahui Li
Department of Cardiology, The First Affiliated Hospital of Ningbo University
6 shared publicationsNan Zheng
Department of Cardiology, Ningbo No.2 Hospital, Ningbo, Zhejiang, China
6 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1949156
Epicardial adipose tissue native T1 and LVEF improvement across BMI categories in HFrEF: an exploratory CMR study
Objective: To explore whether the association between regional epicardial adipose tissue (EAT) native T1 and improvement in left ventricular ejection fraction (LVEF) differs according to body mass index (BMI) category in patients with heart failure with reduced ejection fraction (HFrEF). Methods: This single-center retrospective exploratory study included 119 patients with clinically diagnosed HFrEF and a baseline cardiovascular magnetic resonance (CMR) LVEF < 40%. Improvement was defined as ≥10 percentage points higher follow-up than baseline echocardiographic LVEF, using the last eligible examination at 3–18 months. BMI was categorized using a cutoff of 24 kg / m 2 . Four BMI–EAT native T1 categories based on the cohort median T1 were used only descriptively. The primary logistic model included a BMI category × standardized continuous EAT native T1 interaction, adjusting for age, sex, baseline echocardiographic LVEF, EAT volume index (EATVi), and the CMR-to-baseline echocardiography interval. BMI-specific effects came from the same model; sensitivity analyses used Firth regression and alternative follow-up, exposure, and outcome specifications. Results: Overall, 53 patients met the criterion for LVEF improvement, including 16 of 52 patients (30.8%) with BMI < 24 kg / m 2 and 37 of 67 (55.2%) with BMI ≥ 24 kg / m 2 . The interaction term yielded an odds ratio of 0.396 (95% CI, 0.161–0.975; Wald P = 0.044), and inclusion of the interaction improved model fit (LR P = 0.037). For each 1-SD higher EAT native T1, the BMI-specific ORs were 1.407 (95% CI, 0.776–2.551; P = 0.261) for BMI < 24 kg / m 2 and 0.557 (95% CI, 0.284–1.092; P = 0.088) for BMI ≥ 24 kg/m 2 . Separate sensitivity analyses excluding patients with recorded follow-up CRT/CRT-D or jointly adjusting for baseline AF diagnosis and continuous eGFR, including Firth estimation of the joint model, yielded interaction point estimates close to the primary estimate, with CIs including 1. Uncertainty remained in the approximately 6-month window and continuous Δ LVEF analyses. Conclusion: The association between regional EAT native T1 and LVEF improvement may vary according to BMI category in HFrEF. However, the BMI-specific associations were imprecisely estimated and sensitivity analyses showed variable precision. These findings are hypothesis generating and require independent confirmation in larger prospective cohorts using standardized imaging methods.
- 9 November 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1949156
Open AccessEpicardial adipose tissue native T1 and LVEF improvement across BMI categories in HFrEF: an exploratory CMR study
Objective: To explore whether the association between regional epicardial adipose tissue (EAT) native T1 and improvement in left ventricular ejection fraction (LVEF) differs according to body mass index (BMI) category in patients with heart failure with reduced ejection fraction (HFrEF). Methods: This single-center retrospective exploratory study included 119 patients with clinically diagnosed HFrEF and a baseline cardiovascular magnetic resonance (CMR) LVEF < 40%. Improvement was defined as ≥10 percentage points higher follow-up than baseline echocardiographic LVEF, using the last eligible examination at 3–18 months. BMI was categorized using a cutoff of 24 kg / m 2 . Four BMI–EAT native T1 categories based on the cohort median T1 were used only descriptively. The primary logistic model included a BMI category × standardized continuous EAT native T1 interaction, adjusting for age, sex, baseline echocardiographic LVEF, EAT volume index (EATVi), and the CMR-to-baseline echocardiography interval. BMI-specific effects came from the same model; sensitivity analyses used Firth regression and alternative follow-up, exposure, and outcome specifications. Results: Overall, 53 patients met the criterion for LVEF improvement, including 16 of 52 patients (30.8%) with BMI < 24 kg / m 2 and 37 of 67 (55.2%) with BMI ≥ 24 kg / m 2 . The interaction term yielded an odds ratio of 0.396 (95% CI, 0.161–0.975; Wald P = 0.044), and inclusion of the interaction improved model fit (LR P = 0.037). For each 1-SD higher EAT native T1, the BMI-specific ORs were 1.407 (95% CI, 0.776–2.551; P = 0.261) for BMI < 24 kg / m 2 and 0.557 (95% CI, 0.284–1.092; P = 0.088) for BMI ≥ 24 kg/m 2 . Separate sensitivity analyses excluding patients with recorded follow-up CRT/CRT-D or jointly adjusting for baseline AF diagnosis and continuous eGFR, including Firth estimation of the joint model, yielded interaction point estimates close to the primary estimate, with CIs including 1. Uncertainty remained in the approximately 6-month window and continuous Δ LVEF analyses. Conclusion: The association between regional EAT native T1 and LVEF improvement may vary according to BMI category in HFrEF. However, the BMI-specific associations were imprecisely estimated and sensitivity analyses showed variable precision. These findings are hypothesis generating and require independent confirmation in larger prospective cohorts using standardized imaging methods.
- Open Access
- 9 January 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (1) , e71016
TRIM52 Protects Against Doxorubicin‐Induced Cardiac Inflammation, Oxidative Stress and Cardiac Injury
Tripartite motif 52 (TRIM52) has been identified as a key regulator of inflammatory responses. However, its involvement in doxorubicin (DOX)‐induced cardiotoxicity (DIC) and the underlying molecular mechanisms remain poorly understood. To investigate the functional role of TRIM52, we employed an adeno‐associated virus serotype 9 (AAV9) delivery system to achieve cardiac‐specific Trim52 knockout via tail‐vein injection. C57BL/6 mice received intraperitoneal DOX (5 mg/kg, administered once a week, with a total cumulative dose of 15 mg/kg). Myocardial injury was evaluated by histopathological assessment and molecular profiling of cardiac tissues, complemented by in vitro mechanistic studies using neonatal mouse cardiomyocytes. In vivo and in vitro studies revealed that DOX treatment significantly upregulated TRIM52 expression. Trim52 deficiency effectively mitigated DOX‐induced cardiac injury and dysfunction, concomitantly attenuating oxidative stress and inflammatory responses. Mechanistically, Trim52 deletion markedly enhanced PI3K and AKT phosphorylation, indicating that PI3K/AKT pathway activation underlies the cardioprotective effects of TRIM52 deficiency. Our findings demonstrate that TRIM52 deletion activates PI3K/AKT signalling and attenuates DOX‐induced oxidative and inflammatory myocardial damage. These data identify TRIM52 as a potential therapeutic target for mitigating DIC.
- 9 January 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (1) , e71016
Open AccessTRIM52 Protects Against Doxorubicin‐Induced Cardiac Inflammation, Oxidative Stress and Cardiac Injury
Tripartite motif 52 (TRIM52) has been identified as a key regulator of inflammatory responses. However, its involvement in doxorubicin (DOX)‐induced cardiotoxicity (DIC) and the underlying molecular mechanisms remain poorly understood. To investigate the functional role of TRIM52, we employed an adeno‐associated virus serotype 9 (AAV9) delivery system to achieve cardiac‐specific Trim52 knockout via tail‐vein injection. C57BL/6 mice received intraperitoneal DOX (5 mg/kg, administered once a week, with a total cumulative dose of 15 mg/kg). Myocardial injury was evaluated by histopathological assessment and molecular profiling of cardiac tissues, complemented by in vitro mechanistic studies using neonatal mouse cardiomyocytes. In vivo and in vitro studies revealed that DOX treatment significantly upregulated TRIM52 expression. Trim52 deficiency effectively mitigated DOX‐induced cardiac injury and dysfunction, concomitantly attenuating oxidative stress and inflammatory responses. Mechanistically, Trim52 deletion markedly enhanced PI3K and AKT phosphorylation, indicating that PI3K/AKT pathway activation underlies the cardioprotective effects of TRIM52 deficiency. Our findings demonstrate that TRIM52 deletion activates PI3K/AKT signalling and attenuates DOX‐induced oxidative and inflammatory myocardial damage. These data identify TRIM52 as a potential therapeutic target for mitigating DIC.
- 3 January 2026
- Published by MyJove Corporation
- No. 227,p. e69756
JoVE Video Dataset
Heart failure (HF) remains a major global health challenge, with limited effective treatments targeting its core pathophysiological mechanisms. In this study, an integrated multiomics approach combining Mendelian randomization (MR) and single-cell RNA sequencing (scRNA-seq) was used to identify potential biomarkers and therapeutic targets for HF. We utilized data from genome-wide association studies (GWASs), expression quantitative trait loci (eQTLs), methylation quantitative trait loci (mQTLs), and protein quantitative trait loci (pQTLs) to investigate the genetic mechanisms of HF. Single-cell RNA sequencing was performed to analyse gene expression in cardiac macrophages, and pseudotime analysis was used to study the dynamic regulation of DBNL during macrophage differentiation. Molecular docking and dynamics simulations identified pirinixic acid (WY-14643; PubChem CID: 4594; synonyms: 50892-23-4; WY-14643) as a potential regulator of DBNL. Multiomics analysis revealed that DBNL (Drebrin-like) is a key gene associated with HF risk. Single-cell RNA sequencing revealed that DBNL is expressed mainly in cardiac macrophages and is upregulated under pathological conditions. The expression of DBNL by macrophages is associated with immune metabolism and profibrotic pathways, particularly the IL-6/JAK/STAT3, PI3K/AKT/mTOR, and TGF-β signalling pathways. Pseudotime analysis indicated that DBNL has a dynamic regulatory effect on macrophage differentiation, especially in chronic inflammation. Molecular docking and dynamic simulations have shown that pyridine acid has a potential role in regulating DBNL. This study elucidates the role of DBNL in the progression of heart failure and suggests its potential as a therapeutic target. Importantly, the therapeutic relevance is inferred from computational predictions. These findings offer novel insights into immune metabolism and macrophage-mediated intercellular communication, establishing a theoretical basis for future applications in the optimization of DBNL-targeted drugs and functional research. Nonetheless, additional experimental validation and preclinical studies are needed to substantiate the clinical efficacy of DBNL as a therapeutic target.
- 3 January 2026
- Published by MyJove Corporation
- No. 227,p. e69756
JoVE Video Dataset
Heart failure (HF) remains a major global health challenge, with limited effective treatments targeting its core pathophysiological mechanisms. In this study, an integrated multiomics approach combining Mendelian randomization (MR) and single-cell RNA sequencing (scRNA-seq) was used to identify potential biomarkers and therapeutic targets for HF. We utilized data from genome-wide association studies (GWASs), expression quantitative trait loci (eQTLs), methylation quantitative trait loci (mQTLs), and protein quantitative trait loci (pQTLs) to investigate the genetic mechanisms of HF. Single-cell RNA sequencing was performed to analyse gene expression in cardiac macrophages, and pseudotime analysis was used to study the dynamic regulation of DBNL during macrophage differentiation. Molecular docking and dynamics simulations identified pirinixic acid (WY-14643; PubChem CID: 4594; synonyms: 50892-23-4; WY-14643) as a potential regulator of DBNL. Multiomics analysis revealed that DBNL (Drebrin-like) is a key gene associated with HF risk. Single-cell RNA sequencing revealed that DBNL is expressed mainly in cardiac macrophages and is upregulated under pathological conditions. The expression of DBNL by macrophages is associated with immune metabolism and profibrotic pathways, particularly the IL-6/JAK/STAT3, PI3K/AKT/mTOR, and TGF-β signalling pathways. Pseudotime analysis indicated that DBNL has a dynamic regulatory effect on macrophage differentiation, especially in chronic inflammation. Molecular docking and dynamic simulations have shown that pyridine acid has a potential role in regulating DBNL. This study elucidates the role of DBNL in the progression of heart failure and suggests its potential as a therapeutic target. Importantly, the therapeutic relevance is inferred from computational predictions. These findings offer novel insights into immune metabolism and macrophage-mediated intercellular communication, establishing a theoretical basis for future applications in the optimization of DBNL-targeted drugs and functional research. Nonetheless, additional experimental validation and preclinical studies are needed to substantiate the clinical efficacy of DBNL as a therapeutic target.
- 2 January 2026
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 227,p. e69756
Molecular Mechanisms of DBNL in Heart Failure: From Macrophage Immunometabolism to Therapeutic Implications
Heart failure (HF) remains a major global health challenge, with limited effective treatments targeting its core pathophysiological mechanisms. In this study, an integrated multiomics approach combining Mendelian randomization (MR) and single-cell RNA sequencing (scRNA-seq) was used to identify potential biomarkers and therapeutic targets for HF. We utilized data from genome-wide association studies (GWASs), expression quantitative trait loci (eQTLs), methylation quantitative trait loci (mQTLs), and protein quantitative trait loci (pQTLs) to investigate the genetic mechanisms of HF. Single-cell RNA sequencing was performed to analyse gene expression in cardiac macrophages, and pseudotime analysis was used to study the dynamic regulation of DBNL during macrophage differentiation. Molecular docking and dynamics simulations identified pirinixic acid (WY-14643; PubChem CID: 4594; synonyms: 50892-23-4; WY-14643) as a potential regulator of DBNL. Multiomics analysis revealed that DBNL (Drebrin-like) is a key gene associated with HF risk. Single-cell RNA sequencing revealed that DBNL is expressed mainly in cardiac macrophages and is upregulated under pathological conditions. The expression of DBNL by macrophages is associated with immune metabolism and profibrotic pathways, particularly the IL-6/JAK/STAT3, PI3K/AKT/mTOR, and TGF-β signalling pathways. Pseudotime analysis indicated that DBNL has a dynamic regulatory effect on macrophage differentiation, especially in chronic inflammation. Molecular docking and dynamic simulations have shown that pyridine acid has a potential role in regulating DBNL. This study elucidates the role of DBNL in the progression of heart failure and suggests its potential as a therapeutic target. Importantly, the therapeutic relevance is inferred from computational predictions. These findings offer novel insights into immune metabolism and macrophage-mediated intercellular communication, establishing a theoretical basis for future applications in the optimization of DBNL-targeted drugs and functional research. Nonetheless, additional experimental validation and preclinical studies are needed to substantiate the clinical efficacy of DBNL as a therapeutic target.
- 2 January 2026
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 227,p. e69756
Molecular Mechanisms of DBNL in Heart Failure: From Macrophage Immunometabolism to Therapeutic Implications
Heart failure (HF) remains a major global health challenge, with limited effective treatments targeting its core pathophysiological mechanisms. In this study, an integrated multiomics approach combining Mendelian randomization (MR) and single-cell RNA sequencing (scRNA-seq) was used to identify potential biomarkers and therapeutic targets for HF. We utilized data from genome-wide association studies (GWASs), expression quantitative trait loci (eQTLs), methylation quantitative trait loci (mQTLs), and protein quantitative trait loci (pQTLs) to investigate the genetic mechanisms of HF. Single-cell RNA sequencing was performed to analyse gene expression in cardiac macrophages, and pseudotime analysis was used to study the dynamic regulation of DBNL during macrophage differentiation. Molecular docking and dynamics simulations identified pirinixic acid (WY-14643; PubChem CID: 4594; synonyms: 50892-23-4; WY-14643) as a potential regulator of DBNL. Multiomics analysis revealed that DBNL (Drebrin-like) is a key gene associated with HF risk. Single-cell RNA sequencing revealed that DBNL is expressed mainly in cardiac macrophages and is upregulated under pathological conditions. The expression of DBNL by macrophages is associated with immune metabolism and profibrotic pathways, particularly the IL-6/JAK/STAT3, PI3K/AKT/mTOR, and TGF-β signalling pathways. Pseudotime analysis indicated that DBNL has a dynamic regulatory effect on macrophage differentiation, especially in chronic inflammation. Molecular docking and dynamic simulations have shown that pyridine acid has a potential role in regulating DBNL. This study elucidates the role of DBNL in the progression of heart failure and suggests its potential as a therapeutic target. Importantly, the therapeutic relevance is inferred from computational predictions. These findings offer novel insights into immune metabolism and macrophage-mediated intercellular communication, establishing a theoretical basis for future applications in the optimization of DBNL-targeted drugs and functional research. Nonetheless, additional experimental validation and preclinical studies are needed to substantiate the clinical efficacy of DBNL as a therapeutic target.
- Open Access
- 7 August 2025
- Published by Wiley
Role of Myocardium-Derived Exosomal miRNAs in Doxorubicin-Induced Cardiomyopathy
Background: Doxorubicin-induced cardiomyopathy (DCM) remains a major clinical challenge, highlighting the need for early diagnostic biomarkers. Exosomal miRNAs have emerged as promising candidates because of their stability and regulatory roles in cardiovascular diseases. Methods: Exosomes were isolated from myocardial tissue samples of DOX-treated and control rats using differential ultracentrifugation and were subsequently characterized by transmission electron microscopy (TEM), Western blotting, and nanoparticle tracking analysis (NTA). Differentially expressed miRNAs were screened by microarray analysis. The miRanda algorithm was used to predict target genes, followed by functional enrichment analysis. qRT‒PCR validated selected miRNAs and their target genes. Results: Doxorubicin administration induced significant cardiac dysfunction, characterized by decreased left ventricular ejection fraction (LVEF) and increased serum levels of cardiac biomarkers (cTnI, BNP, and CK-MB). Microarray profiling revealed 26 differentially expressed miRNAs, and KEGG enrichment analysis indicated enrichment in the MAPK signaling pathway. qRT‒PCR demonstrated upregulation of exosomal miR-182 and downregulation of Taok2 mRNA, a key MAPK gene. ROC analysis indicated the potential of exosomal miR-182 for DCM diagnosis. Conclusion: Exosomal miR-182 may serve as a diagnostic marker for DCM. Bioinformatic analyses predict its potential regulation of the MAPK pathway through Taok2 targeting, although this mechanistic relationship requires experimental validation. These findings provide new perspectives for the early monitoring of DCM.
- 7 August 2025
- Published by Wiley
Open AccessRole of Myocardium-Derived Exosomal miRNAs in Doxorubicin-Induced Cardiomyopathy
Background: Doxorubicin-induced cardiomyopathy (DCM) remains a major clinical challenge, highlighting the need for early diagnostic biomarkers. Exosomal miRNAs have emerged as promising candidates because of their stability and regulatory roles in cardiovascular diseases. Methods: Exosomes were isolated from myocardial tissue samples of DOX-treated and control rats using differential ultracentrifugation and were subsequently characterized by transmission electron microscopy (TEM), Western blotting, and nanoparticle tracking analysis (NTA). Differentially expressed miRNAs were screened by microarray analysis. The miRanda algorithm was used to predict target genes, followed by functional enrichment analysis. qRT‒PCR validated selected miRNAs and their target genes. Results: Doxorubicin administration induced significant cardiac dysfunction, characterized by decreased left ventricular ejection fraction (LVEF) and increased serum levels of cardiac biomarkers (cTnI, BNP, and CK-MB). Microarray profiling revealed 26 differentially expressed miRNAs, and KEGG enrichment analysis indicated enrichment in the MAPK signaling pathway. qRT‒PCR demonstrated upregulation of exosomal miR-182 and downregulation of Taok2 mRNA, a key MAPK gene. ROC analysis indicated the potential of exosomal miR-182 for DCM diagnosis. Conclusion: Exosomal miR-182 may serve as a diagnostic marker for DCM. Bioinformatic analyses predict its potential regulation of the MAPK pathway through Taok2 targeting, although this mechanistic relationship requires experimental validation. These findings provide new perspectives for the early monitoring of DCM.
- 15 February 2025
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (1) , 97-106
Downregulated TRIM35 Alleviates Doxorubicin-Induced Cardiotoxicity by Suppressing Oxidative Stress and Inflammation via Inhibiting TLR4/NF-κB Pathway
Purpose The use of doxorubicin (DOX), a potent chemotherapy drug, is limited by its detrimental effects on the heart. This cardiotoxicity is primarily driven by oxidative stress and inflammation. TRIM35 plays a key role in inflammatory responses; however, its exact function in DOX-induced cardiotoxicity (DIC) remains to be fully understood. This study investigates the effects of TRIM35 on DIC and explores the underlying biological mechanisms. Methods To assess the role of TRIM35, we reduced the expression of TRIM35 in the heart tissues of mice using an adeno-associated virus 9 (AAV9) system, delivered through tail vein injection. We then administered weekly doses of DOX (4 mg/kg) to C57BL/6 mice for 4 weeks to induce DIC. Echocardiography, histopathological assessments, and molecular techniques were employed to examine the effects and mechanisms of TRIM35 on DIC. Results Our research found that DOX treatment increases TRIM35 levels in the heart. By lowering TRIM35 expression, we observed an improvement in cardiac function and a decrease in myocardial damage in DOX-treated mice. Additionally, reduced TRIM35 expression lessened myocardial hypertrophy and fibrosis. It also mitigated the oxidative stress and inflammation caused by DOX. Furthermore, the down-regulation of TRIM35 expression resulted in the downregulation of TLR4 and phosphorylated P65 expression. Conclusion Downregulated TRIM35 expression mitigates the oxidative stress and inflammation caused by DOX, likely through impacting the TLR4/NF-κB signaling pathway. These insights indicate that TRIM35 holds promise as a therapeutic target for managing heart damage induced by DOX.
- 15 February 2025
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (1) , 97-106
Downregulated TRIM35 Alleviates Doxorubicin-Induced Cardiotoxicity by Suppressing Oxidative Stress and Inflammation via Inhibiting TLR4/NF-κB Pathway
Purpose The use of doxorubicin (DOX), a potent chemotherapy drug, is limited by its detrimental effects on the heart. This cardiotoxicity is primarily driven by oxidative stress and inflammation. TRIM35 plays a key role in inflammatory responses; however, its exact function in DOX-induced cardiotoxicity (DIC) remains to be fully understood. This study investigates the effects of TRIM35 on DIC and explores the underlying biological mechanisms. Methods To assess the role of TRIM35, we reduced the expression of TRIM35 in the heart tissues of mice using an adeno-associated virus 9 (AAV9) system, delivered through tail vein injection. We then administered weekly doses of DOX (4 mg/kg) to C57BL/6 mice for 4 weeks to induce DIC. Echocardiography, histopathological assessments, and molecular techniques were employed to examine the effects and mechanisms of TRIM35 on DIC. Results Our research found that DOX treatment increases TRIM35 levels in the heart. By lowering TRIM35 expression, we observed an improvement in cardiac function and a decrease in myocardial damage in DOX-treated mice. Additionally, reduced TRIM35 expression lessened myocardial hypertrophy and fibrosis. It also mitigated the oxidative stress and inflammation caused by DOX. Furthermore, the down-regulation of TRIM35 expression resulted in the downregulation of TLR4 and phosphorylated P65 expression. Conclusion Downregulated TRIM35 expression mitigates the oxidative stress and inflammation caused by DOX, likely through impacting the TLR4/NF-κB signaling pathway. These insights indicate that TRIM35 holds promise as a therapeutic target for managing heart damage induced by DOX.
- Open Access
- 28 November 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 986, 177156
Identification of hsa_circ_0076957 and miR-4512-targeted COL19A1 as regulators in clopidogrel resistance among stable coronary heart disease patients through comprehensive circRNA and miRNA analysis
- 28 November 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 986, 177156
Open AccessIdentification of hsa_circ_0076957 and miR-4512-targeted COL19A1 as regulators in clopidogrel resistance among stable coronary heart disease patients through comprehensive circRNA and miRNA analysis
- Open Access
- 1 January 2024
- Published by Indian Pharmaceutical Association - IPA
- Vol. 86 (S1) , 277-286
Impact of Xuefu Zhuyu Decoction on Reducing Hyporesponsiveness of Aspirin in Acute Coronary Syndrome
The main objective of this study is to evaluate the effect of Xuefu Zhuyu decoction on aspirin resistance in acute coronary syndrome patients. We enrolled 45 patients with aspirin resistance and divided them randomly into control group (group A) and treatment group (group B). We applied Xuefu Zhuyu decoction to the group B for 4 w. Before treatment and after 4 w of treatment, we evaluated the platelet reactivity, and performed biochemical and molecular biology analyses from both subgroups. Through logistic regression analysis, we assessed the association between improvement of platelet function and confounding factors. Lastly, clinical follow-ups for 1 mo and 12 mo were performed to analysis the therapeutic effects. We found the aspirin reaction unit was clearly on decline 602.35±26.49 vs. 542.48±43.09 (before treatment vs. after treatment; p<0.001) in group B. Through quantitative reverse transcription-polymerase chain reaction and radioimmunoassay, we assessed the expression of cyclooxygenase-1 and thromboxane A2, and the results indicated that after treatment, the thromboxane A2 decreased 503.4±12.0 vs. 447.8±48.5 (before treatment vs. after treatment; p<0.001). In group B, hemorheology improved significantly, and plasma viscosity, whole blood viscosity along with fibrinogen decreased significantly (all p<0.01). Meanwhile, in group B, the glucose was correlated with aspirin reaction unit and the expression of thromboxane A2 was a protective factor of aspirin reaction unit, and aspirin resistance patients would suffer less major adverse cardiac events (p=0.024). Xuefu Zhuyu decoction might reduce hyporesponsiveness of aspirin by inhibiting thromboxane A2 and improve the hemorheological index, which are of great significance for the prevention in cardiovascular events.
- 1 January 2024
- Published by Indian Pharmaceutical Association - IPA
- Vol. 86 (S1) , 277-286
Open AccessImpact of Xuefu Zhuyu Decoction on Reducing Hyporesponsiveness of Aspirin in Acute Coronary Syndrome
The main objective of this study is to evaluate the effect of Xuefu Zhuyu decoction on aspirin resistance in acute coronary syndrome patients. We enrolled 45 patients with aspirin resistance and divided them randomly into control group (group A) and treatment group (group B). We applied Xuefu Zhuyu decoction to the group B for 4 w. Before treatment and after 4 w of treatment, we evaluated the platelet reactivity, and performed biochemical and molecular biology analyses from both subgroups. Through logistic regression analysis, we assessed the association between improvement of platelet function and confounding factors. Lastly, clinical follow-ups for 1 mo and 12 mo were performed to analysis the therapeutic effects. We found the aspirin reaction unit was clearly on decline 602.35±26.49 vs. 542.48±43.09 (before treatment vs. after treatment; p<0.001) in group B. Through quantitative reverse transcription-polymerase chain reaction and radioimmunoassay, we assessed the expression of cyclooxygenase-1 and thromboxane A2, and the results indicated that after treatment, the thromboxane A2 decreased 503.4±12.0 vs. 447.8±48.5 (before treatment vs. after treatment; p<0.001). In group B, hemorheology improved significantly, and plasma viscosity, whole blood viscosity along with fibrinogen decreased significantly (all p<0.01). Meanwhile, in group B, the glucose was correlated with aspirin reaction unit and the expression of thromboxane A2 was a protective factor of aspirin reaction unit, and aspirin resistance patients would suffer less major adverse cardiac events (p=0.024). Xuefu Zhuyu decoction might reduce hyporesponsiveness of aspirin by inhibiting thromboxane A2 and improve the hemorheological index, which are of great significance for the prevention in cardiovascular events.
- Open Access
- 15 December 2023
- Published by Springer Nature in Clinical Epigenetics
- Vol. 15 (1) , 1-19
Transcriptome-wide map of N6-methyladenosine (m6A) profiling in coronary artery disease (CAD) with clopidogrel resistance
Background: Clopidogrel resistance profoundly increases the risk of major cardiovascular events in coronary artery disease (CAD) patients. Here, we comprehensively analyse global m6A modification alterations in clopidogrel-resistant (CR) and non-CR patients. Methods: After RNA isolation, the RNA transcriptome expression (lncRNA, circRNA, and mRNA) was analysed via RNA-seq, and m6A peaks were identified by MeRIP-seq. The altered m6A methylation sites on mRNAs, lncRNAs, and circRNAs were identified, and then, GO and KEGG pathway analyses were performed. Through joint analysis with RNA-seq and MeRIP-seq data, differentially expressed mRNAs harbouring differentially methylated sites were identified. The changes in m6A regulator levels and the abundance of differentially methylated sites were measured by RT-PCR. The identification of m6A-modified RNAs was verified by m6A-IP-qPCR. Results: The expression of 2919 hypermethylated and 2519 hypomethylated mRNAs, 192 hypermethylated and 391 hypomethylated lncRNAs, and 375 hypermethylated and 546 hypomethylated circRNAs was shown to be altered in CR patients. The m6A peaks related to CR indicated lower mark density at the CDS region. Functional enrichment analysis revealed that inflammatory pathways and insulin signalling pathways might be involved in the pathological processes underlying CR. The expression of mRNAs (ST5, KDM6B, GLB1L2, and LSM14B), lncRNAs (MSTRG.13776.1 and ENST00000627981.1), and circRNAs (hsa_circ_0070675_CBC1, hsa-circRNA13011-5_CBC1, and hsa-circRNA6406-3_CBC1) was upregulated in CR patients, while the expression of mRNAs (RPS16 and CREG1), lncRNAs (MSTRG.9215.1), and circRNAs (hsa_circ_0082972_CBC1) was downregulated in CR patients. Moreover, m6A regulators (FTO, YTHDF3, and WTAP) were also differentially expressed. An additional combined analysis of gene expression and m6A peaks revealed that the expression of mRNAs (such as ST5, LYPD2, and RPS16 mRNAs) was significantly altered in the CR patients. Conclusion: The expression of m6A regulators, the RNA transcriptome, and the m6A landscape was altered in CR patients. These findings reveal epitranscriptomic regulation in CR patients, which might be novel therapeutic targets in future.
- 15 December 2023
- Published by Springer Nature in Clinical Epigenetics
- Vol. 15 (1) , 1-19
Open AccessTranscriptome-wide map of N6-methyladenosine (m6A) profiling in coronary artery disease (CAD) with clopidogrel resistance
Background: Clopidogrel resistance profoundly increases the risk of major cardiovascular events in coronary artery disease (CAD) patients. Here, we comprehensively analyse global m6A modification alterations in clopidogrel-resistant (CR) and non-CR patients. Methods: After RNA isolation, the RNA transcriptome expression (lncRNA, circRNA, and mRNA) was analysed via RNA-seq, and m6A peaks were identified by MeRIP-seq. The altered m6A methylation sites on mRNAs, lncRNAs, and circRNAs were identified, and then, GO and KEGG pathway analyses were performed. Through joint analysis with RNA-seq and MeRIP-seq data, differentially expressed mRNAs harbouring differentially methylated sites were identified. The changes in m6A regulator levels and the abundance of differentially methylated sites were measured by RT-PCR. The identification of m6A-modified RNAs was verified by m6A-IP-qPCR. Results: The expression of 2919 hypermethylated and 2519 hypomethylated mRNAs, 192 hypermethylated and 391 hypomethylated lncRNAs, and 375 hypermethylated and 546 hypomethylated circRNAs was shown to be altered in CR patients. The m6A peaks related to CR indicated lower mark density at the CDS region. Functional enrichment analysis revealed that inflammatory pathways and insulin signalling pathways might be involved in the pathological processes underlying CR. The expression of mRNAs (ST5, KDM6B, GLB1L2, and LSM14B), lncRNAs (MSTRG.13776.1 and ENST00000627981.1), and circRNAs (hsa_circ_0070675_CBC1, hsa-circRNA13011-5_CBC1, and hsa-circRNA6406-3_CBC1) was upregulated in CR patients, while the expression of mRNAs (RPS16 and CREG1), lncRNAs (MSTRG.9215.1), and circRNAs (hsa_circ_0082972_CBC1) was downregulated in CR patients. Moreover, m6A regulators (FTO, YTHDF3, and WTAP) were also differentially expressed. An additional combined analysis of gene expression and m6A peaks revealed that the expression of mRNAs (such as ST5, LYPD2, and RPS16 mRNAs) was significantly altered in the CR patients. Conclusion: The expression of m6A regulators, the RNA transcriptome, and the m6A landscape was altered in CR patients. These findings reveal epitranscriptomic regulation in CR patients, which might be novel therapeutic targets in future.